NCT07295691

Autologous Serum Eye Drops in Dry Eye Syndrome

Autologous Serum Eye Drops in Dry Eye Syndrome: Clinical Efficacy and Safety Evaluation

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: The General Authority for Teaching Hospitals and Institutes · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the clinical efficacy and safety of autologous serum eye drops (ASEDs) in patients with moderate-to-severe dry eye syndrome who are refractory to conventional artificial tear therapy.

Detailed description

Dry Eye Syndrome (DES) is a highly prevalent ocular condition that significantly affects quality of life, with global prevalence estimated at 5%-50%, depending on population and diagnostic criteria. Autologous Serum Eye Drops (ASEDs) have emerged as a promising therapy due to their composition, which is rich in vitamin A, epidermal growth factor, fibronectin, and transforming growth factor-β. These components mimic natural tears and promote epithelial healing, reduce inflammation, and enhance tear film stability.

Conditions

• Autologous Serum Eye Drops
• Dry Eye Syndrome

Interventions

Type	Name	Description
OTHER	Autologous Serum Eye Drop	Participants will receive eye drops prepared from their blood serum following a standardized protocol. Specifically, 40 mL of venous blood was collected from each participant at the start of the study and centrifuged at 3000 rpm for 15 min.

Timeline

• Start date: 2025-09-01
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2025-12-22
• Last updated: 2025-12-22

Locations

1 site across 1 country: Egypt